BREAST CANCER BASE

The advantages of endocrine therapy
Practice has proved that even breast cancer patients after surgery no visible clinical metastases, but a considerable number of patients already exists subclinical metastases. These lesions may develop into a certain period of clinical metastases and threatened the lives of the patients. At present, the auxiliary has become endocrine therapy after surgery for breast cancer patients to receive long-term chances of survival of the most important, if not the only valuable systemic treatment. Because hormone receptor positive or unknown to the patients, supporting endocrine therapy to reduce the risk of recurrence and death risk was crammed with the role of chemotherapy, and its toxicity is much more relaxed.

No chemotherapy directly with Femara work? The world at present, after receptor-positive breast cancer patients using complementary therapy — endocrine therapy more effective, if it can first before using six regular cycle of adequate chemotherapy work better.
Surgery has been recycling for many years femara work? Generally speaking after the surgery, first six cycles of chemotherapy, followed by adjuvant endocrine therapy done.
If surgery has been for many years, so now propose to go Femara treatment. Can follow-up observation.

Chemotherapy is used Femara can be used? Chemotherapy is used when sufficient quantities should be completed chemotherapy, the use of endocrine therapy such as letrozole.

Tamoxifen (TAM) is the widespread clinical application is a safe and effective anti-estrogen drugs.
More than tamoxifen for hormone receptor-positive cases, the efficiency can be as high as 55% to 60%, while receptor-negative efficient only 10%. Tamoxifen for Postmenopausal cases efficacy than pre-menopausal good. Studies have shown that tamoxifen as the first choice for breast cancer and effective endocrine treatment, in many countries have become postmenopausal breast cancer patients at the front line of drug treatment. Generally considered the therapeutic use of tamoxifen for two years, preferably five years or more. A large number of foreign scholars to the clinical observation that tamoxifen treatment for breast cancer can be indefinite delivery date or until relapse.
A common dose tamoxifen for each 10 to 20 mg three times a day, continuous oral 2 to 5 years.
Tamoxifen common side effects : nausea, vomiting, facial flushing, headache, dizziness and occasional alopecia, leukopenia, thrombocytopenia, perineal itching, vaginal bleeding or discharge, the patient, there may be some visual impairment, eye pain, influencing the optic nerve.
Some academics have suggested Tamoxifen can cause endometrial cancer, but are still disputed this view. 

The general view has been dubbed "the first lady killer" of breast cancer is not only anti-administration with him. But with the development of research, Zhongshan in southern China two homes hepatobiliary Hospital Breast Cancer Center, Professor Su every tin has proposed, the latest international medical study found that tamoxifen to prevent breast cancer is the most promising means!